Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Long-Term, Rollover Extension Study of Rovalpituzumab Tesirine

Trial Profile

A Multicenter, Long-Term, Rollover Extension Study of Rovalpituzumab Tesirine

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rovalpituzumab tesirine (Primary) ; Dexamethasone
  • Indications Small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors AbbVie
  • Most Recent Events

    • 29 Aug 2019 Status changed from recruiting to discontinued.According to an AbbVie media release, the company discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program
    • 23 May 2019 Planned number of patients changed from 80 to 20.
    • 20 Dec 2018 Planned End Date changed from 30 Aug 2023 to 5 Feb 2024.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top